2020
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Harrington K, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Gumuscu B, Swaby R, Burtness B. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6505-6505. DOI: 10.1200/jco.2020.38.15_suppl.6505.Peer-Reviewed Original ResearchPD-L1 CPSSubsequent anticancer therapyM HNSCCMedian PFS2Subsequent therapyRecurrent/metastatic headNeck squamous cell carcinomaNext-line therapyObjective tumor progressionImmune checkpoint inhibitorsFirst-line therapyKaplan-Meier methodAnticancer therapySquamous cell carcinomaCox regression modelTotal populationKEYNOTE-048Superior OSCheckpoint inhibitorsMetastatic headSystemic therapyComparable safetyCell carcinomaFavorable safetyPatient outcomes
2013
Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.Peer-Reviewed Original ResearchConceptsDisease-free survivalFox Chase Cancer CenterModerate dysplasiaOverall survivalLocal controlOral tongueSevere dysplasiaMild dysplasiaActuarial local controlInferior local controlKaplan-Meier methodOral tongue cancerWorse local controlSquamous cell carcinomaEarly-stage cancerAdditional therapyMeier methodResection marginsSubsequent therapyEntire cohortTongue cancerCancer CenterCell carcinomaPathology reportsFinal margins
2012
Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue
Sopka D, Li T, Lango M, Mehra R, Burtness B, Flieder D, Ridge J, Galloway T. Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s205. DOI: 10.1016/j.ijrobp.2012.07.531.Peer-Reviewed Original Research